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Abstract: Cancer gene therapy consists of numerous approaches where the common 
denominator is utilization of vectors for achieving therapeutic effect. A particularly potent 
embodiment of the approach is virotherapy, in which the replication potential of an 
oncolytic virus is directed towards tumor cells to cause lysis, while normal cells are spared. 
Importantly, the therapeutic effect of the initial viral load is amplified through viral 
replication cycles and production of progeny virions. All cancer gene therapy approaches 
rely on a sufficient level of delivery of the anticancer agent into target cells. Thus, 
enhancement of delivery to target cells, and reduction of delivery to non-target cells, in an 
approach called transductional targeting, is attractive. Both genetic and non-genetic 
retargeting strategies have been utilized. However, in the context of oncolytic viruses, it is 
beneficial to have the specific modification included in progeny virions and hence genetic 
modification may be preferable. Serotype chimerism utilizes serotype specific differences 
in receptor usage, liver tropism and seroprevalence in order to gain enhanced infection of 
target tissue. This review will focus on serotype chimeric adenoviruses for cancer gene 
therapy applications. 
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1. Introduction  
Significant reductions in cancer mortality have been achieved by improving cancer prevention, 
early diagnosis and treatments. Nevertheless, incidence rates continue to rise and cancer is already the 
most common cause of death in many countries, causing approximately 6.7 million deaths annually 
worldwide [1]. Moreover, traditional cancer therapeutics are associated with undesirable and even  
life-threatening side effects. Also, significant cross-resistance exists between different 
chemotherapeutics, underlining the need for novel therapy approaches. 
While perhaps only 5% of cancers are hereditary, on the molecular level cancer is always a genetic 
disease resulting from the accumulation of mutations in various key regulatory genes. Therefore, gene 
therapy approaches have become a rational focus of interest in developing cancer treatments. 
Traditionally, cancer gene therapy has aimed at transferring a gene for correction of the disease 
phenotype or to express therapeutic molecules inside or near the target cell. Virotherapy is a slightly 
different approach, where the replicating virus itself is the therapeutic agent, incorporating 
amplification of the therapeutic effect from the initial viral dose. However, oncolytic viruses are often 
armed with therapeutic molecules to combine the benefits of gene delivery with the more potent 
oncolytic platform.  
Replicating adenoviruses have shown excellent patient safety in clinical trials [2-5], but 
unfortunately efficacy has been variable, especially in the context of systemic delivery. The success of 
cancer gene therapy is dependent on the ability of the vector to deliver the therapeutic gene (or viral 
genome in the case of oncolytic viruses) into the target tissue. Unfortunately, there are various factors 
that prevent systemically delivered viruses from reaching their target, and therefore extensive research 
efforts have focused on improving the delivery of adenoviral vectors. In the context of oncolytic 
virotherapy, genetic engineering is the only feasible means to modify viruses for tropism alteration or 
expansion, as the whole approach depends on the production of progeny virions which should display 
the qualities the injected virus displays. The goal of engineering vectors is to create a single-
component agent that can efficiently transduce and kill target cells. Serotype chimerism of vectors is a 
conceptually elegant approach utilizing serotypic differences in receptor usage and serotype-specific 
immunity. Serotype chimerism allows targeting to receptors distinct from the coxsackie adenovirus 
receptor (CAR), which is frequently downregulated in advanced tumors. Important goals also include 
de-targeting of the liver and avoidance of pre-existing neutralizing antibodies.  
2. Factors affecting the outcome of systemic delivery of Ad5 
There are over 50 different serotypes of adenoviruses that were originally classified depending on 
their ability to neutralize serum to cross-block them. They can be further divided into six different 
subgroups A-F based on their ability to agglutinate erythrocytes of different species and on their 
oncogenicity in rodents (adenoviruses are not oncogenic in humans). Viruses from different subgroups 
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have distinct tropisms, implying distinct receptor usage. Group C adenoviruses, including serotype 5 
adenovirus (Ad5), the most widely utilized serotype in cancer gene therapy, utilize the coxsackie-
adenovirus receptor (CAR) as a primary attachment molecule [6,7]. Later it was demonstrated that also 
group A, D, E and F adenoviruses use CAR [7], though not all of them as a primary receptor [8,9]. The 
expression levels of CAR correlate with the susceptibility of a particular cell type to Ad infection [10]. 
Loss of CAR expression correlates with tumor progression [11], resulting in low expression in 
advanced disease and subsequently variable gene transfer efficacy. Moreover, Ad5 vector 
biodistribution in vivo does not seem to depend on CAR distribution [12]. Various blood coagulation 
factors, such as vitamin K-dependent factors VII, IX and X (FVII, FIX and FX, respectively) as well 
as complement protein C4BP have been shown to play a role in tropism by bridging adenovirus to cell 
surface receptors, especially on hepatocytes and liver Kupffer cells (KCs) [13-16]. When treating 
metastatic disease, systemic delivery would be appealing and therefore liver tropism might be a major 
barrier for the systemic use of Ad5 based vectors [17-19]. However, these aspects are only known in 
mice and it is unclear if they accurately represent the human situation. Neutralizing antibody (NAb) 
response to Ad5 is also a major determinant of the fate of systemically delivered virus [20,21], which 
may be relevant as the majority of humans have been exposed to Ad5 and many have circulating  
Ad5-specific NAbs.  
2.1. Tumor targeting by fiber serotype chimerism 
Various Ad5 capsid locales have been genetically modified to enhance tumor transduction. The 
fiber knob domain is principally responsible for binding CAR, and thus the Ad5 fiber protein has been 
the primary focus of genetic modification [22]. Different serotypes have significant similarities in the 
fiber architecture [23,24] which allows the creation of chimeric vectors, where the whole fiber or only 
the knob region is switched to that of another serotype (Figure 1). Fiber chimeras using non-CAR 
binding knobs display CAR independent transduction and recognize alternate receptors. 
2.1.1. Fiber chimerism 
Several groups have studied the feasibility of fiber chimerism in terms of viral tropism alteration 
(Table 1). Even before CAR was identified as the primary receptor for Ad5 in 1997 [6], the 
replacement of its fiber with that of Ad7 was shown to be feasible due to homology in the fiber tail 
regions [25]. Ad7 fiber expanded the tropism of the chimeric Ad5/7 vector towards a distinct receptor 
and allowed infection of CAR deficient dendritic cells (DCs). Subsequently, it was shown that Ad7 
and other group B adenoviruses utilize either CD46 or receptor X as the primary attachment molecule 
instead of CAR [26,27]. The subdivision of subgroup B viruses into species B1 (serotypes 3, 7, 16, 21 
and 50) and B2 (serotypes 11, 14, 34 and 35) was based on genetic differences [28]. CD80 and CD86 
have also been proposed as receptors for species B adenoviruses [29,30]. Tuve et al. suggested a 
revised classification of subgroup B viruses based on their receptor usage [27]. According to this 
division, group I serotype B adenoviruses utilize CD46 (serotypes 16, 21, 35 and 50), group II 
adenoviruses utilize receptor X (serotypes 3, 7p and 14), and group III Ad11p utilizes both.  
Subgroup B viruses do not use CAR, and therefore the efforts to construct serotype chimeric viruses 
have largely focused on exploiting them, though viruses from all subgroups have been utilized 
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(Table 1). To this end, replacing the Ad5 fiber with that of subgroup B Ad35 resulted in enhanced 
infectivity of hematopoietic stem cells [31]. More importantly, wild type Ad35 displayed efficient in 
vitro cytotoxicity in prostate, breast, liver and ovarian cancer cells [32]. When mice bearing 
subcutaneous prostate cancer tumors were treated intratumorally or intravenously with wild type 
Ad35, however, no significant anti-tumor effect was witnessed, nor was there any impact on survival. 
The authors concluded that expression levels and accessibility of the primary receptor CD46 is not the 
sole determinant of Ad35 infectivity and anticancer activity in vivo.  
Figure 1. The principal of serotype chimeric fiber modifications. Depicted from left to 
right are the wild type Ad5 capsid, Ad5 capsid featuring the knob from a distinct serotype 
and Ad5 capsid featuring the shaft and knob from a different serotype. 
 
 
The fiber from another subgroup B virus, Ad16p, was found to confer enhanced gene transfer by 
Ad5 based vectors to cardiovascular and synovial tissues [33]. Importantly, a recent study 
demonstrated efficient transduction of brain tumor cell lines and CD133+ “tumor initiating cells” by 
Ad16p [34]. Another subgroup B virus, Ad11p, was shown to efficiently infect and kill prostate, 
breast, liver and ovarian cancer cells in vitro [32]. Furthermore, chimeric Ad5/11p was shown to kill 
oral and esophagus cancer cells in vitro [35]. Importantly, systemically delivered wild type Ad11p 
resulted in a significant survival benefit in the same murine model of prostate cancer, where Ad35 
failed [32].  
2.1.2. Knob chimerism 
Substitution of the knob region instead of the entire fiber is a variation of the serotype chimerism 
approach. One such virus is the serotype 3 chimeric Ad5/3, which has the Ad5 fiber knob replaced by 
Ad3 knob [36,37]. Retaining the Ad5 fiber shaft may be beneficial, as it has been shown that the 
length of the shaft plays a crucial role in adenoviral infectivity [38]. The long Ad5 shaft may be 
superior to a short shaft, in the context of the Ad5 backbone, as the shorter shaft might result in 
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charge-dependent repulsion between exposed negatively charged Ad5 hexon loops and the acidic  
cell-surface. Therefore, changing only the knob region but retaining the long Ad5 shaft is an appealing 
approach to retarget the virus from CAR but to take advantage of the favorable effect the longer shaft 
length may have on infectivity. Indeed, Ad5/3 chimeric virus has been shown to display enhanced 
gene transfer in various cancer models, including prostate cancer, ovarian cancer, breast cancer, gastric 
cancer and renal cancer [37,39-43]. Enhanced gene transfer efficacy was translated into improved cell 
killing efficacy with an oncolytic Ad5/3-Δ24 in an orthotopic murine model of ovarian cancer [44]. 
Furthermore, Ad5/3-Δ24 and its various tissue specific promoter controlled variants displayed 
effective antitumor activity against tumors derived from CD44+/CD24-/low breast cancer initiating cells 
[45,46]. Ad5/3-Δ24 has also been tested in several other tumor types with impressive efficacy results 
[39,41-44,47]. In addition to a chimeric fiber, Ad5/3-Δ24 features a 24 base pair deletion in E1A 
conserved region 2 (CR2). Dysfunctional E1A is incapable of binding and releasing transcription 
factor E2F1 from retinoblastoma (Rb), leading to attenuated replication in quiescent normal cells. The 
Rb/p16 pathway is universally disrupted in cancer cells [48], and, thus, free E2F1 is abundant in 
cancer cells, allowing replication of Δ24-viruses in most solid tumors. 
2.2. Liver detargeting by serotype chimerism 
The liver is the most relevant organ with regard to adenovirus associated toxicity as corroborated by 
a fatality in an adenoviral gene therapy trial [54]. Adenoviruses can cause severe toxicity in 
immunocompromised individuals [55]. In mice, Ad5 displays liver tropism that adversely affects its 
availability after systemic delivery [17,19]. In humans, the biodistribution of adenovirus is not known.  
Hepatocyte transduction ablation has been attempted with various capsid modifications. Smith and 
colleagues created a mutation in the Ad5 HSPG binding fiber shaft KKTK motif that resulted in 
reduced liver tropism in mice, rats and non-human primates [56,57]. Various attempts to modify in 
vivo tropism by abolishing CAR interactions have failed in avoiding the liver tropism of Ad5 [58,59]. 
Furthermore, Ad5 knob replacement with serotype 3 knob does not significantly alter Ad5 liver 
tropism, though CAR binding is abrogated [39,41-43], implying that the presence of CAR is not a 
critical factor in determining the susceptibility of tissues to adenovirus in vivo. Blood factors serving 
as a bridge between the virus and liver cells may allow efficient liver transduction despite CAR 
binding ablation [13,14]. Hexon has been suggested to have a major role in Ad5 liver tropism and 
recent studies have clarified the high-affinity interaction of FX with hexon in FX-mediated liver gene 
transfer [16,60]. This suggests that using viruses based on other serotypes with weaker binding 
between hexon and coagulation factors would reduce liver tropism. Indeed, other serotypes than Ad5 
conferred decreased FX binding to hexon, with subgroup B Ad35 and Ad3 binding FX weakly and 
subgroup D Ad48 and Ad26 not binding FX at all [16,61]. Hexon chimeric Ad5/Ad6-gag and 
Ad5/Ad12-gag vectors were not neutralized with Ad5 NAbs, suggesting that hexon contains the major 
antigenic determinants for NAbs [62]. However, the hexon chimerism approach seemed feasible only 
when the hexon switch was performed within the same subgroup, suggesting lack of adequate 
structural similarity between different subgroups. Recently, it has been shown that mutation of critical 
amino acids from two hypervariable regions in hexon eliminates FX binding and subsequent FX-
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mediated liver gene transfer in mice [63], which further highlights the role of hexon in liver tropism of 
Ad5 based vectors.  
Table 1. Selected serotype chimeric adenoviruses.  
Virus Subgroup Capsid 
modification 
Receptor / 
Specific homing 
Results Ref. 
Ad5/7 C/B1 Ad7 fiber CD46 infection of CAR deficient DC [25] 
Ad5/35 C/B1 Ad35 fiber CD46 Infection of CAR-deficient CD34+ 
hematopoietic stem cells. 
[31] 
Ad5/35S 
Ad5/35L 
Ad5/9S 
Ad5/9L 
C/B1 
C/B1 
C/C 
C/C 
Ad35 fiber 
Ad35 knob 
Ad9 fiber 
Ad9 knob 
CD46 
CD46 
CAR 
CAR 
Hepatocyte transduction was 
independent of the interaction with 
CAR and reduced 10 fold with short 
shaft. 
[49] 
Ad5.Fib12 
Ad5.Fib16 
Ad5.Fib35 
Ad5.Fib50 
Ad5.Fib7 
Ad5.Fib11 
Ad5.Fib10 
Ad5.Fib17 
Ad5.Fib24 
Ad5.Fib30 
Ad5.Fib33 
Ad5.Fib37 
Ad5.Fib38 
Ad5.Fib47 
Ad5.Fib40S 
C/A 
C/B1 (I) 
C/B1 (I) 
C/B1 (I) 
C/B1 (II) 
C/B2 (III) 
C/D 
C/D 
C/D 
C/D 
C/D 
C/D 
C/D 
C/D 
C/F 
Ad12 fiber 
Ad16 fiber 
Ad35 fiber 
Ad50 fiber 
Ad7 fiber 
Ad11p fiber 
Ad10 fiber 
Ad17 fiber 
Ad24 fiber 
Ad30 fiber 
Ad33 fiber 
Ad37 fiber 
Ad38 fiber 
Ad47 fiber 
Ad40 short 
fiber 
CD46 
CD46 
CD46 
CD46 
receptor X 
receptor X and 
CD46 
sialic acid 
sialic acid 
sialic acid 
sialic acid 
sialic acid 
sialic acid 
sialic acid 
sialic acid 
unknown 
Increased transduction of patient-
derived glioma cells with serotype 35, 
16, 50 and 11 chimeras. 
 
 
 
 
 
 
 
[50] 
 
 
 
 
 
 
 
ColoAd1 
(oncolytic) 
B1/B2 
(II)/(III) 
major capsid 
proteins from 
Ad11p 
receptor X and 
CD46 
Directed evolution resulted in an 
Ad11p virus with a nearly complete E3 
region deletion, smaller deletion in E4 
and a chimeric Ad3/Ad11p E2B 
region. Over 2 log increase in potency 
and selectivity when compared to 
ONYX-015 on colon cancer cell lines 
and in vivo. 
[51] 
Ad5/3luc1 C/B1 Ad5 fiber, 
Ad3 knob 
receptor X Enhanced gene transfer to various 
cancer cell lines and primary tumor 
tissues. 
[37,39,41-
43] 
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Table 1. Cont. 
Virus Subgroup Capsid 
modification 
Receptor / 
Specific homing 
Results Ref. 
Ad5/3-Δ24 
(oncolytic) 
C/B1 Ad5 fiber, 
Ad3 knob 
receptor X Enhanced cell killing of cancer cell 
lines and xenograft tumors. 
[39,41-44] 
Ad5/19p-HIT C/D Ad19p fiber, 
HIT peptide 
sialic acid, phage 
display-selected 
for homing to 
kidneys 
Enhanced gene transfer to renal cancer 
cell lines and xenograft renal cancer 
tumors in vivo, decreased gene transfer 
to liver 
[9,52] 
Ad5/3-Δ24 
-GMCSF 
C/B1 Ad5 fiber, 
Ad3 knob 
receptor X Enhanced cell killing of cancer cell 
lines and syngeneic hamster tumors. 
Objective clinical benefit in 8/12 
patients with progressing 
chemotherapy refractory solid tumors 
as evaluated by radiology with 
RECIST criteria 
[53] 
 
However, contradicting results were obtained when in vivo phage display and capsid engineering 
were combined to develop a renal-targeted Ad5/19p-HIT vector, which had been proposed to be 
promising for systemic delivery to renal tumors [52,64]. This vector displayed lower FIX and FX 
binding and reduced hepatic tropism, and, importantly, favorable tumor-to-liver transduction ratios in 
murine models of renal cancer when compared to Ad5 even though it featured intact Ad5 hexon. These 
results suggest that the role of Ad5 fiber in liver tropism should not be overlooked. It has been 
postulated that interactions between FIX and fiber [64] or the length of the shaft may also play major 
roles in hepatocyte transduction. Shortness of the shaft has previously been reported to affect liver 
tropism of fiber modified vectors [49] and the Ad19p shaft is the same length as Ad35 shaft [65]. The 
effect of shaft length is corroborated by a finding that subgroup C Ad6 does not induce liver toxicity in 
mice [32] although its hexon binds to FX with the same efficiency as Ad5 [16]. Ad6 fiber shaft is three 
β-turn repeats shorter than that of Ad5 [66]. 
2.3. Avoidance of pre-existing immunity by serotype chimerism 
Human Ads have been classified into over 50 serotypes based on lack of cross-neutralization. The 
majority of humans have been exposed to Ads, resulting in immunological memory. Also, 40-97% of 
the human population present neutralizing antibodies (NAbs) against Ad5 [67]. Adenovirus NAb titers 
vary by detection method and geographic location and are higher in non-US and non-European 
countries [68]. NAbs bind to capsid proteins and block Ad internalization by target cells, and elicit 
induced uptake to Fc-receptor bearing immune cells such as kupffer cells (KCs) and dendritic cells 
(DCs), resulting in rapid vector clearance and inflammatory responses [69,70]. Innate immune 
responses and pre-existing immunity against Ads are major determinants of the fate of systemically 
delivered Ads [20,21], and although pre-existing immunity does not seem to adversely affect the anti-
tumor efficacy of locally delivered Ad [71], high NAb titer may compromise systemic delivery [72]. 
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Furthermore, in naïve individuals, NAbs develop against viral capsid proteins within weeks after virus 
encounter thus complicating systemic re-administration.  
The first serotype chimeric vector reported, Ad5/7, displayed unaltered neutralizing immune 
responses, suggesting that NAbs generated against fiber do not constitute a significant fraction of the 
total NAb population. Indeed, the seroprevalence of rare human Ads is significantly lower than of 
Ad5, with less than 7 % of humans presenting NAbs against Ad35, for example [73].  
Since the bulk of neutralizing antibody response is directed against hexon [74], the most abundant 
capsid protein, fiber chimeric Ad5 vectors may still face the problem of pre-existing immunity. There 
are contradicting studies, however, that suggest a significant role also for anti-fiber NAbs in 
determining the success of gene transfer in vivo, especially in the context of low NAb titers [75]. For 
example, an Ad5/3 [36] vector featuring serotype 3 knob was shown to achieve effective gene transfer 
in Ad5 pre-immunized mice, perhaps highlighting the crucial role of knob in mediating infection [75]. 
A study corroborating the importance of anti-fiber antibodies showed that an Arg-Gly-Asp (RGD) 
modification in the HI-loop of Ad5 fiber allowed partial escape from NAbs present in the ascites fluid 
[76]. Moreover, anti-fiber antibodies recognize conformational epitopes of the trimeric form of the 
fiber, and thus even modest changes to the knob may cause critical alterations in the three-dimensional 
structure, thus avoiding antibody recognition [77]. The putative requirement of anti-fiber antibodies 
for productive synergism with other NAbs may be important. 
3. Clinical Use of Serotype Chimeric Viruses 
Only a few chimeric viruses have entered clinical use. All published data are derived from the use 
of two replicating viruses, Ad5/3-COX2L-Δ24 and Ad5/3-Δ24-GMCSF, both of which feature the 
serotype 3 knob in an Ad5 backbone [53,78-80] (Table 2). Both viruses harbor a 24 bp deletion in E1A 
CR2, targeting viral replication to cells with a defective Rb/p16 pathway. Furthermore, 
Ad5/3-COX2L-Δ24 also features a cyclo-oxygenase 2 promoter (COX2L) controlling the expression 
of E1A, and Ad5/3-Δ24-GMCSF has the granulocyte macrophage colony stimulating factor (GM-
CSF) gene inserted into the E3 region to evoke antitumor immunity. Previously, a GMCSF-producing 
oncolytic virus (Ad5-D24-GMCSF) with a wt capsid was shown to induce tumor-specific immunity in 
an immunocompetent syngeneic hamster model semipermissive for human adenoviruses [81]. Prior to 
clinical studies, also the chimeric Ad5/3-Δ24-GMCSF was studied for selectivity and efficacy in 
immunocompetent hamsters [53]. The virus was effective in hindering the growth of aggressive 
syngeneic pancreatic tumors, with and without low-dose cyclophoshamide used to reduce regulatory 
T-cells. Tumor-selective replication and transgene expression was demonstrated by measuring an 
increase in viral copy number and GMCSF production in intratumorally injected tumors, while there 
was no increase in either in the liver.  
Patients with various cancer types and advanced solid tumors were treated with Ad5/3-COX2L-Δ24 
and Ad5/3-Δ24-GMCSF with excellent safety [53,79,80]. Mostly mild, grade 1-2 symptoms were 
encountered with total viral doses of up to 3 × 1011 VP. Objective evidence of antitumor activity 
ranging from 61% to 67% was seen after a single round of treatment [53,80]. Specifically, 
Ad5/3-COX2L-Δ24 treatments resulted in one partial response and one minor response in five of the 
radiologically evaluable patients [79,80]. Several other patients had decreases in tumor markers and 
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overall, 11/18 patients had evidence of anti-tumor activity. An increase in viral copy number was seen 
in the serum of 11/17 evaluable patients two days or later post treatment compared to day 1, suggesting 
viral replication. Rapid induction of Ad5/3 NAbs was observed in patients within three weeks of 
treatment and titers remained high for several weeks. High NAb titers, however, did not prevent 
Ad5/3-COX2L-Δ24 from replicating in tumors as viral genomes and increasing NAb titers could be 
measured in blood concurrently in many patients.  
Table 2. Clinical use of serotype chimeric viruses. 
Virus Capsid 
modification/Other 
modifications 
Cancer/Patients 
(N) 
Highest 
dose 
Delivery 
route 
Results Ref. 
Ad5/3-
COX2L-Δ24 
Ad5 fiber, Ad3 knob 
/ the Cox2-promoter 
contolling E1A with 
a 24bp deletion 
Progressing 
chemotherapy 
refractory solid 
tumors /18 
3 × 1011 
VP 
i.v., i.t., 
i.c. 
Antitumor activity in 61% 
of patients; measured 
according to RECIST 
criteria or as tumor 
markers 
[80] 
Ad5/3-
COX2L-Δ24 
Ad5 fiber, Ad3 knob 
/ the Cox2-promoter 
contolling E1A with 
a 24bp deletion 
Chemotherapy 
refractory high 
risk non- 4-S, 
stage 4 
neuroblastoma 
with lymph node 
metastasis/1 
1 × 1011 
VP 
i.t., into 
lymph 
node, 
i.v. 
Primary tumor regression 
by 71%, complete response 
in bone marrow. 
[79] 
Ad5/3-Δ24-
GMCSF 
Ad5 fiber, Ad3 
knob/ E1A with a 
24bp deletion, 
GMCSF in E3 
Progressing 
chemotherapy 
refractory solid 
tumors/ 21 
4 × 1011 
VP 
i.t, 1/5 of 
the dose 
i.v. 
Antitumor activity in 67% 
of evaluable (12) patients 
by radiological assessment, 
reduction of tumor marker 
values in 2 patients. 
Resolution of ascites and 
pleural effusion formation 
in 2 patients. 
[53] 
i.v. = intravenous; i.t. = intratumoral;  i.c. = intracavitary 
 
Treatment with Ad5/3-Δ24-GMCSF resulted in objective clinical benefit in 8/12 patients as 
evaluated by radiology with Response Evaluation Criteria In Solid Tumors (RECIST) criteria [53]. 
Increases in the blood titer of Ad5/3-Δ24-GMCSF when compared to day 1 were seen in 8/15 patients, 
suggesting viral replication. NAbs increased in all patients, but no correlation was seen between NAb 
titers and viral dose, virus shedding in blood, antitumor activity, or toxicity. Increases in CD8+ 
lymphocytes against Ad5 were seen, suggesting that adaptive cellular responses can be produced even 
in patients with advanced disease. Furthermore, CD8+ cells against a tumor epitope survivin increased 
in the majority of the patients, suggesting that an antitumor immune response was also evoked.  
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4. Conclusions  
Ad5 is the most commonly used platform for the development of oncolytic adenoviruses for the 
treatment of cancer. Serotype chimerism may be a useful means to increase efficacy of the approach. It 
can be utilized to circumvent the dependence on CAR and influence the liver tropism of viruses, 
although not all reports agree on the latter. Also, the type of chimera may determine the presence or 
absence of an effect on mouse liver tropism. Chimeras may also be useful for avoiding pre-existing 
serotype specific antibodies and some chimeras may be less immunogenic than others. The importance 
of hexon/FX interactions in liver tropism have been demonstrated [16,63], indicating that swapping 
merely the Ad5 fiber to that of another serotype would not result in abolished liver tropism. 
Furthermore, FX binding is postulated to be specifically associated with the hexon hypervariable 
regions [63], suggesting that small modifications in hexon amino acids might eliminate liver 
transduction. Furthermore, the role of Ad5 fiber in liver tropism via binding to FIX [64] and through 
the KKTK interaction with heparin sulfate proteoglycans (HSPG) [56] should not be underestimated. 
NAb responses against various capsid proteins seem relevant in determining the fate of systemically 
delivered adenoviruses, thereby encouraging further development of serotype chimeric vectors. Such 
viruses could also feature modifications in the hexon hypervariable region if Ad5 is used as the 
platform for vector development. For assessing the relevance of preclinical studies, it would be key to 
understand biodistribution and the presence or absence of adenevirus liver tropism in humans.  
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